Prospective Randomized Trial of Treatment for Adult Patients with Intermediate-severity IgA Nephropathy Using Multiple-drug Combined Therapy with or without Mizoribine (MZB)

摘要

Background and methods ： We conducted a prospective randomized multicenter trial to evaluate the efficacy and safety of multiple-drug combined therapy with or without mizoribine (MZB) for adult patients with intermediate-severity immunoglobulin A nephropathy (IgAN).Results ： Forty-five patients, 20 in Group A (corticosteroid, ACEI/ARB, anti-platelet agents) and 25 in Group B (same medication as Group A plus MZB as an immunosuppressant) ,were enrolled. The baseline characteristics of the patients did not differ significantly between the groups. Thirty-six patients (lbm Group A and 20 m Group B) completed 2 years of follow-up. After initiation of the treatments, urinary protein (UP) levels fell in both groups, but the fluctuation of UP stabilized over time in Group B. The rate of clinical remission at 12 months was significantly nigher in Group B (40%) than in Group A (7 %) (p = 0.049) ， but the difference was no longer significant at 24 months. Renal function did not change in either of the groups. Adverse events were observed in 2 Group A patients (10%) and 4 Group B patients (16%), but none were serious and were related to corticosteroid.